Afraxis, Inc.
SAN DIEGO, CA · Founded 2007 · CIK 0001435673 · Medtech
Enhanced Spine Profiling (ESP) platform: automated high-throughput in vivo imaging and analysis of dendritic spine morphometry for CNS drug discovery
afraxis.com →- Grants
- $205K
- 1 award
- Sector median: 1
- Raised
- $2.9M
- 5 Form D · Apr 2012
- 174 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 19
- 1 granted · 18 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200820102012201420162018
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $750,001 | |
| Private capital raised | Form D · SEC | $1,200,000 | |
| Private capital raised | Form D · SEC | $650,000 | |
| Private capital raised | Form D · SEC | $300,000 | |
| Private capital raised | Form D · SEC | $45,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid circuit level dendritic spine morphometric analysis for in vivo pharmacology in CNS drug discovery | $204,508 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 862 | SOLTA MEDICAL INC | — | $47M |
| 863 | Gelesis | — | $38M |
| 864 | FUSmobile | — | — |
| 865 | Afraxis, Inc. | — | $2.9M |
| 866 | ORTHOBOND CORPORATION | — | $12M |
| 867 | WINTER INNOVATIONS INC. | — | $2.1M |
| 868 | Boston Heart Diagnostics Corp | — | $10M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Braden BohrmanDirector
- Braden BohrmannDirector
- David CampbellExecutive Officer
- Doug DownsExecutive Officer
- Douglas DownsExecutive Officer
- Steve HeinemannDirector
- Steve Heinemann, Ph.DDirector
- Jay LichterDirector · Executive Officer
- Court TurnerDirector · Executive Officer
Patents
- Distributed Anatomical Image Analysisgranted
- Pak Inhibitors For The Treatment Of Cancerapplication
- 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ones For The Treatment Of Nervous System Disorders And Cancerapplication
- Methods For Treating Neurological Conditionsapplication
- 6-(ETHYNYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES For The Treatment Of Cns Disordersapplication
- 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES For The Treatment Of Cns Disordersapplication
- 8-(2'-HETEROCYCYL)PYRIDO[2.3-D]PYRIMIDIN-7(8H)-ONES For The Treatment Of Cns Disordersapplication
- 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES For The Treatment Of Cns Disordersapplication
- 8-(HETEROARYLMETHYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES For The Treatment Of Cns Disordersapplication
- Methods For Treating Autismapplication
- Methods For Treating Mild Cognitive Impairmentapplication
- 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES For The Treatment Of Cns Disordersapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.